Isolyte S pH 7.4
RxNorm 800925· SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, SODIUM PHOSPHATE, DIBASIC, AND POTASSIUM PHOSPHATE· INTRAVENOUS
B. Braun Medical Inc.
Indications and usage
INDICATIONS AND USAGE This solution is indicated for use in adults as a source of electrolytes and water for hydration, and as an alkalinizing agent.
Dosage and administration
DOSAGE AND ADMINISTRATION This solution is for intravenous use only. Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. Isolyte ® S pH 7.4 (Multi-Electrolyte Injection) may be admixed with solutions which contain phosphate or which have been supplemented with phosphate. The presence of magnesium and phosphate ions in this solution should be considered when phosphate is present in the additive solution, in order to avoid precipitation. Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Warnings
WARNINGS The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema. In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention. Solutions containing potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present. Solutions containing gluconate or acetate should be used with great care in patients with metabolic or respiratory alkalosis and in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.
Contraindications
CONTRAINDICATIONS Contraindications: None known. Accurate clinical and laboratory estimation of fluid and electrolyte balance in order to access benefit/risk ratio are essential prior to administration of this solution (see WARNINGS and PRECAUTIONS ).
Drug interactions
Drug Interactions Sodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-retaining patients. Administration of barbiturates, narcotics, hypnotics or systemic anesthetics should be adjusted with caution in patients also receiving magnesium-containing solutions because of an additive central depressive effect. Parenteral magnesium should be administered with extreme caution to patients receiving digitalis preparations.
Pregnancy
Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with Isolyte ® S pH 7.4 (Multi-Electrolyte Injection). It is also not known whether Isolyte ® S pH 7.4 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Isolyte ® S pH 7.4 should be given to a pregnant woman only if clearly needed.
Nursing mothers
Nursing Mothers Caution should be exercised when Isolyte ® S pH 7.4 (Multi-Electrolyte Injection) is administered to a nursing woman.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- atrial fibrillation9
- bradycardia8
- caesarean section1
- exposure during pregnancy1
Adverse reactions (label)
ADVERSE REACTIONS Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain and diarrhea. The signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities and cardiac arrest. Potassium deficits result in disruption of neuromuscular function, and intestinal ileus and dilatation. If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect. Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany and muscular hyperexcitability. Abnormally high plasma levels of magnesium can result in flushing, sweating, hypotension, circulatory collapse, and depression of cardiac and central nervous system function. Respiratory depression is the most immediate threat to life. Magnesium deficits can result in tachycardia, hypertension, hyperirritability and psychotic behavior. The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
KR · 한국Products in Korea (107)
- 네오클티어점안액(주)대웅제약
- 네오클티어점안액(주)대웅제약
- 네오클티어점안액(주)대웅제약
- 뮤로128점안액2%(염화나트륨)(주)바슈헬스코리아
- 뮤로128점안액5%(염화나트륨)(주)바슈헬스코리아
- 아이소프트점안액(주)바이넥스
- 스마일오투티얼즈점안액(주)바이넥스
- 아이소프트점안액(주)바이넥스
- 아이소프트점안액(주)바이넥스
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 스마일오투티얼즈점안액(주)옵투스제약
- 스마일오투티얼즈점안액(주)옵투스제약
- 스마일오투티얼즈점안액(주)옵투스제약
- 옵티어즈점안액(주)유한메디카
View more: Full FDA label on DailyMed →Label effective 20231006